SPRB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Spruce Biosciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 41.69. The higher Degree of Financial Leverage, the more volatile earnings will be.
The industry rank for Spruce Biosciences's Degree of Financial Leverage or its related term are showing as below:
The historical data trend for Spruce Biosciences's Degree of Financial Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Degree of Financial Leverage | Get a 7-Day Free Trial | -0.90 | 0.42 | 0.12 | 0.98 | -9.88 |
Spruce Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Degree of Financial Leverage | Get a 7-Day Free Trial | -0.16 | -1.36 | -1.91 | -9.88 | 41.69 |
For the Biotechnology subindustry, Spruce Biosciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Degree of Financial Leverage distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Degree of Financial Leverage falls into.
Spruce Biosciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:
Degree of Financial Leverage | = | % Change in Earnings per Share (Diluted)** | / | % Change in EBIT |
= | ( -1.13 (Mar. 2024) / -1.86 (Mar. 2023) - 1 ) | / | ( -46.304 (Mar. 2024) / -46.744 (Mar. 2023) - 1 ) | |
= | -0.3925 | / | -0.0094 | |
= | 41.69*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Spruce Biosciences (NAS:SPRB) Degree of Financial Leverage Explanation
Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.
The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.
Be Aware
The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.
Thank you for viewing the detailed overview of Spruce Biosciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Percival Barretto-ko | director | 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
Charlton Ralph William Iii | officer: Chief Medical Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104 |
Javier B. Szwarcberg | director, officer: Chief Executive Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014 |
Kirk Ways | director | C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014 |
Camilla V Simpson | director | 20 ELAINE AVE., MILL VALLEY CA 94941 |
Bali Muralidhar | director | C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077 |
Jonas Hansson | director | 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006 |
Rivervest Venture Fund Iii (ohio), L.p. | 10 percent owner | 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502 |
Healthcap Viii, L.p. | 10 percent owner | 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006 |
Moghrabi Dina Chaya | director | 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ |
Omega Fund Vi Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Samir M. Gharib | officer: Chief Financial Officer | 2655 PINE STREET, #6, SAN FRANCISCO CA 94115 |
Richard King | director, officer: Chief Executive Officer | C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131 |
From GuruFocus
By Business Wire Business Wire • 01-05-2022
By Business Wire Business Wire • 02-01-2023
By Business Wire • 08-14-2023
By Business Wire Business Wire • 05-22-2023
By Business Wire Business Wire • 08-30-2022
By Business Wire Business Wire • 04-11-2022
By Business Wire Business Wire • 01-05-2023
By Business Wire Business Wire • 05-15-2023
By Business Wire Business Wire • 05-24-2023
By Business Wire • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.